Case Challenge

Management of a 39-Year-Old Male With Intermediate-Risk, Chronic-Phase CML

Source: Treatment of Chronic Myeloid Leukemia

Management of a 39-Year-Old Male With Intermediate-Risk, Chronic-Phase CML


Faculty:

  • Michael W.N. Deininger, MD, PhD

CME CREDIT INFORMATION

Release Date: 12/12/06

Expiration Date: 12/11/07


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review the use of imatinib in the frontline treatment of chronic-phase CML
  • Discuss allogeneic hematopoietic stem cell transplant in the setting of chronic-phase CML
  • Discuss appropriate uses of dasatinib in the treatment of chronic-phase CML

Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.